Research Paper Volume 13, Issue 2 pp 2780—2802

Identification of a novel immune microenvironment signature predicting survival and therapeutic options for bladder cancer


Figure 4. Validation of the immune-based risk model in the internal TCGA and external GEO testing cohorts. (A, D) Kaplan-Meier curve analysis of overall survival of high-risk UBC (n=101 for TCGA; n=83 for GSE13507) and low-risk UBC (n=100 for TCGA; n=82 for GSE13507) cases. (B, E) Time-dependent ROC curve analysis showing the 3-year and 5-year survival of the10 IRGs signature. (C, F) Heatmaps showing expression of the selected genes in the immune-based risk model.